LINJARDY 5MG 10MG TAB

Linjardy 5mg/10mg Tablet without any external links:

Linjardy 5mg/10mg Tablet – Dual Therapy for Type 2 Diabetes Management

Linjardy Tablet combines two powerful antidiabetic agents: Empagliflozin (SGLT2 inhibitor) and Linagliptin (DPP-4 inhibitor), designed for adults with type 2 diabetes mellitus to improve glycemic control when diet and exercise alone are insufficient.

Key Features & Benefits

• Dual mechanism of action: Empagliflozin promotes glucose excretion via urine, while Linagliptin increases insulin secretion and decreases glucagon levels.

• Helps lower HbA1c, fasting blood glucose, and postprandial sugar levels.

• Aids in weight reduction and blood pressure control due to SGLT2 effects.

• Low risk of hypoglycemia compared to sulfonylureas or insulin.

• Once-daily dosing for improved patient compliance.

Indications

• For patients with type 2 diabetes mellitus inadequately controlled by monotherapy or combination therapy.

• Also beneficial in reducing cardiovascular risk in diabetic patients with heart disease.

Dosage

• Typically one tablet daily, with or without food.

• Dosage strength (5mg or 10mg empagliflozin) is based on individual glycemic response and renal function.

Safety Information

• Not for use in patients with type 1 diabetes or diabetic ketoacidosis.

• Caution in patients with renal impairment; renal function should be monitored regularly.

• Possible side effects include urinary tract infections, increased urination, nasopharyngitis, and gastrointestinal discomfort.

Packaging

• Available in blister packs containing 14 or 28 tablets, depending on the variant.

• Prescription only – for use under medical supervision.